Results 61 to 70 of about 5,123 (202)

Comparison of Pharmacokinetic, Pharmacodynamic and Tolerability Profiles of CKD-11101, Darbepoetin Alfa (NESP®) Biosimilar, to Those of NESP® After a Single Subcutaneous or Intravenous Administration to Healthy Subjects

Drug Design, Development and Therapy, 2021
Inseung Jeon,1,* Jaeseong Oh,1,* Yu-Kyung Kwon,2 Seo Hyun Yoon,1 Joo-Youn Cho,1 In-Jin Jang,1 Kyung-Sang Yu,1 SeungHwan Lee1 1Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul ...
Jeon I, Oh J, Kwon YK, Yoon SH, Cho JY, Jang IJ, Yu KS, Lee S   +7 more
doaj  

Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus ≥10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial

BMC Cancer, 2009
Background Several studies have shown that darbepoetin alfa, an erythropoiesis-stimulating agent (ESA), can reduce transfusions and increase hemoglobin (Hb) levels in patients with chemotherapy-induced anemia (CIA).
Vermorken Jan, Ludwig Heinz, Bokemeyer Carsten, Gascon Pere, Hedenus Michael, Vansteenkiste Johan, Hamilton Lisa, Bridges Ken, Pujol Beatriz   +8 more
doaj   +1 more source

Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers

CA: A Cancer Journal for Clinicians, Volume 76, Issue 1, January/February 2026.
Abstract The therapeutic landscape for renal cell carcinoma (RCC) and urinary tract cancer (UTC) has transformed dramatically, creating complexity in treatment selection and sequencing. The 2025 Advanced Urologic Cancer Consensus Conference was convened to establish evidence‐based expert consensus recommendations for optimal management.
Rana R. McKay, Sumanta Pal, Wanling Xie, David Aggen, Laurence Albiges, Andrea Apolo, Michael B. Atkins, Rick Bangs, Kathryn E. Beckermann, Joaquim Bellmunt, Stephanie A. Berg, Mehmet A. Bilen, David Braun, Maria I. Carlo, Jason Efstathiou, Matthew Galsky, Petros Grivas, Shilpa Gupta, Naomi Haas, A. Ari Hakimi, Hans Hammers, Daniel Y. C. Heng, Michelle Hirsch, Gopakumar Iyer, Eric Jonasch, Vadim S. Koshkin, Oleksandr N. Kryvenko, Bryan Lewis, Roger Li, Surena Matin, Benjamin Maughan, David F. McDermott, Bradley McGregor, Joshua Meeks, Matthew Milowsky, Robert Motzer, Andrea Necchi, Dan Petrylak, Sima Porten, Thomas Powles, Brian Rini, Brian Shuch, Arlene Siefker‐Radtke, Guru Sonpavde, S. Srikala Sridhar, Cristina Suarez, Chad Tang, Abhishek Tripathi, Michiel S. Van Der Heijden, Martin Voss, Wenxin Xu, Tian Zhang, Jonathan Rosenberg, Toni K. Choueiri   +53 more
wiley   +1 more source

An asymmetric tetrabody is a potent and efficacious agonist of the erythropoietin receptor in vitro and in vivo

Protein Science, Volume 34, Issue 10, October 2025.
Abstract Erythropoietin (EPO) initiates EPO receptor (EPOR) signaling in hematopoietic cells by binding to an asymmetric EPOR dimer through two different sites. We engineered dimeric diabody‐Fc (Db‐Fc) fusion proteins that appeared to act as potent agonists of human EPOR in cell proliferation assays. However, detailed analysis of their oligomeric forms
Jarrett J. Adams, Levi L. Blazer, Jacky Chung, Minoo Karimi, Taylor Davidson, Heather A. Bruce, Alexander U. Singer, Ning Yang, Lia Cardarelli, Isabelle Pot, Luigi Colombo, Lily Jun‐shen Huang, Yue Ma, Stephen W. Michnick, Orson W. Moe, Sachdev S. Sidhu   +15 more
wiley   +1 more source

Carnitine reduced erythropoietin dose required and improved cardiac function of patients on maintenance hemodialysis

Saudi Journal of Kidney Diseases and Transplantation, 2017
Intravenous administration of 2 g carnitine in every hemodialysis (3 times/week), for 8–10 months, reduced doses of darbepoetin alfa required to maintain adequate hemoglobin levels (10–11 g/dL) into 10% of the initial doses.
Yosuke Aoki, Takako Yamamoto
doaj   +1 more source

Uptake of evidence by physicians: De-adoption of erythropoiesis-stimulating agents after the TREAT trial

BMC Nephrology, 2021
Background Variation in de-adoption of ineffective or unsafe treatments is not well-understood. We examined de-adoption of erythropoiesis-stimulating agents (ESA) in anemia treatment among patients with chronic kidney disease (CKD) following new clinical
Khoa Vu, Jiani Zhou, Alexander Everhart, Nihar Desai, Jeph Herrin, Anupam B. Jena, Joseph S. Ross, Nilay D. Shah, Pinar Karaca-Mandic   +8 more
doaj   +1 more source

Strategies for the Management of Postoperative Anemia in Elective Orthopedic Surgery [PDF]

, 2016
Objective: To assess the use of oral iron, intravenous (IV) iron, and erythropoiesis-stimulating agents (ESAs) for the prevention and management of perioperative anemia in elective orthopedic surgery patients, and to provide a clinical algorithm for use.
Howard, Meredith L., Nisly, Sarah A., Steuber, Taylor D.   +2 more
core   +2 more sources

Cost Minimized Immunoaffinity Purification of EPO and Its Analogs in Doping Control—A Step‐by‐Step Protocol for Human Urine and Blood

Drug Testing and Analysis, Volume 17, Issue 9, Page 1545-1559, September 2025.
A cost minimized immunoaffinity protocol was developed, which allows the direct purification of ERAs from human urine. After slight modification, the protocol is also applicable to serum and plasma and is fully compliant with WADA TD2024EPO. Compared to commercial EPO‐purification kits, the material costs are significantly lower.
Christian Reichel, Günter Gmeiner, Mario Thevis   +2 more
wiley   +1 more source

The Use of Darbepoetin to Stimulate Erythropoiesis in the Treatment of Anemia of Chronic Kidney Disease in Dogs

Journal of Veterinary Internal Medicine, 2017
Background Darbepoetin alfa (darbepoetin) is an erythropoiesis‐stimulating agent used for the treatment of anemia secondary to chronic kidney disease (CKD) in dogs, but reports describing response are lacking.
E.H. Fiocchi, L.D. Cowgill, D.C. Brown, J.E. Markovich, S. Tucker, M.A. Labato, M.B. Callan   +6 more
doaj   +1 more source

Use of erythropoiesis stimulating agents [PDF]

, 2014
UNIFESP Hospital São Paulo Setor de HemodiáliseHospital Beneficência PortuguesaUFJF Serviço de Nefrologiacentro de pesquisa IMEPENUNIFESP, Hospital São Paulo Setor de ...
Abreu, Patricia Ferreira, Bastos, Marcus Gomes, Romão Junior, João Egídio   +2 more
core   +3 more sources